Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401008 | 0.85 | CYP1A2 (0.44) | CYP1A2RAB9AL3MBTL1TSHRLMNA | |
| SCHEMBL1401057 | 0.84 | CYP1A2 (0.41) | CYP1A2RAB9AL3MBTL1TSHRLMNA | |
| SCHEMBL7282328 | 0.83 | CYP1A2 (0.40) | CYP1A2RAB9AL3MBTL1TSHRLMNA | |
| SCHEMBL1401271 | 0.83 | DNM1 (0.46) | L3MBTL1TSHRLMNAALDH1A1USP2 | |
| SCHEMBL1477937 | 0.77 | CYP1A2 (0.50) | CYP1A2RAB9AL3MBTL1TSHRLMNA | |
| SCHEMBL31325279 | 0.74 | CYP1A2 (0.59) | CYP1A2RAB9ATSHRALOX5ALDH1A1 | |
| SCHEMBL31357582 | 0.74 | CYP1A2 (0.59) | CYP1A2RAB9ATSHRALOX5ALDH1A1 | |
| SCHEMBL1481090 | 0.74 | CYP1A2 (0.50) | CYP1A2RAB9AL3MBTL1TSHRALOX5 | |
| SCHEMBL9235430 | 0.73 | CYP1A2 (0.46) | CYP1A2RAB9AL3MBTL1TSHRPOLB | |
| SCHEMBL4618714 | 0.72 | CYP1A2 (0.57) | CYP1A2RAB9AL3MBTL1TSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230103337-A1 | MEDICINE FOR IMPROVING STATE OF PREGNANCY, AND USE THEREOF | Yamaguchi, Koushi (JP) | 2023-04-06 | — | — | US | disclosed |
| US-11541040-B2 | Medicine for improving state of pregnancy, and use thereof | Yamaguchi, Kouchi (JP) | 2023-01-03 | — | — | US | disclosed |
| EP-3977995-A1 | TACROLIMUS FOR AMELIORATING PREGNANCY CONDITIONS | Yamaguchi, Koushi (JP) | 2022-04-06 | — | — | EP | disclosed |
| EP-3900729-A1 | AGENT FOR IMPROVING INFERTILITY, RECURRENT MISCARRIAGE, AND STATE OF PREGNANCY | Yamaguchi, Koushi (JP) | 2021-10-27 | — | — | EP | disclosed |
| EP-3246036-B1 | MEDICINE FOR IMPROVING PREGNANCY-INDUCED HYPERTENSION SYNDROME | YAMAGUCHI KOUSHI (JP) | 2021-10-13 | — | — | EP | disclosed |
| US-20210228551-A1 | THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN MATERNOFETAL RELATIONSHIP | YAMAGUCHI KOUSHI (JP) | 2021-07-29 | — | — | US | disclosed |
| EP-3834826-A1 | THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN MATERNO-FETAL RELATIONSHIP | Yamaguchi, Koushi (JP) | 2021-06-16 | — | — | EP | disclosed |
| WO-2020129348-A1 | AGENT FOR IMPROVING INFERTILITY, RECURRENT MISCARRIAGE, AND STATE OF PREGNANCY | 山口 晃史 | 2020-06-25 | — | — | WO | disclosed |
| WO-2020032252-A1 | THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN MATERNO-FETAL RELATIONSHIP | 山口 晃史 | 2020-02-13 | — | — | WO | disclosed |
| US-20190099406-A1 | MEDICINE FOR IMPROVING STATE OF PREGNANCY, AND USE THEREOF | Yamaguchi, Koushi (JP) | 2019-04-04 | — | — | US | disclosed |
| US-5215995-A | For treatment of baldness or alopecia | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-01 | — | — | US | disclosed |
| EP-0536401-A1 | TRICYCLO COMPOUNDS, A PROCESS FOR THEIR PRODUCTION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-04-14 | — | — | EP | disclosed |
| US-5196437-A | Macrolide | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1993-03-23 | — | — | US | disclosed |
| WO-1992013862-A1 | LACTONE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-08-20 | — | — | WO | disclosed |
| EP-0484936-A1 | Suspensions containing tricyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-05-13 | — | — | EP | disclosed |
| EP-0483842-A1 | Pharmaceutical compositions containing tricyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-05-06 | — | — | EP | disclosed |
| US-5110811-A | Antibody inhibitors | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-05-05 | — | — | US | disclosed |
| WO-1992000313-A1 | TRICYCLO COMPOUNDS, A PROCESS FOR THEIR PRODUCTION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-01-09 | — | — | WO | disclosed |
| WO-1991017754-A1 | METHODS FOR TREATING AND PREVENTING INFLAMMATION OF MUCOSA AND BLOOD VESSELS USING FK 506 AND RELATED COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-28 | — | — | WO | disclosed |
| US-4929611-A | ANTIBODY INHIBITORS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103337-A1 | MEDICINE FOR IMPROVING STATE OF PREGNANCY, AND USE THEREOF | PGF, SLC10A1, SLC26A4 | CYP1A2 295/4885RAB9A 2467/4885L3MBTL1 4469/4885 |
| US-20190099406-A1 | MEDICINE FOR IMPROVING STATE OF PREGNANCY, AND USE THEREOF | PGF, SLC10A1, SLC26A4 | CYP1A2 304/4885RAB9A 2360/4885L3MBTL1 4415/4885 |
| US-11541040-B2 | Medicine for improving state of pregnancy, and use thereof | PGF, SLC10A1, SLC26A4 | CYP1A2 304/4885RAB9A 2360/4885L3MBTL1 4415/4885 |
| US-20210228551-A1 | THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN MATERNOFETAL RELATIONSHIP | PGF, HAMP, HLA-DRB1 | CYP1A2 3359/4885RAB9A 987/4885L3MBTL1 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.